Pacira BioSciences, Inc.PCRX stock score: 65/100

$36.48 · +0.00% · Scored Nov 19, 2026

Technical
63
Fundamental
65
News
56

The reading

Pacira BioSciences (PCRX) scores 65 out of 100, which reads neutral, higher than 90% of Healthcare stocks and 90% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 65, technicals 63.

Among the fundamentals, Earnings Growth (Annual) at 100 and Current Ratio at 99 score highest, while Return on Equity (ROE) at 4 weighs the most against it.

News sentiment is neutral at 56; it is shown, not counted in the composite.

Since Aug 23, 2026 the composite has ranged from 48 to 65, and it is up 14 points over the period.

About Pacira BioSciences

Pacira BioSciences (PCRX) is a U.S. pharmaceutical company focused on non-opioid treatments for pain. Its largest product is EXPAREL, a long-acting form of the local anesthetic bupivacaine that surgeons and anesthesiologists inject at the time of surgery to control pain for several days and reduce the need for opioids afterward. Its second product, ZILRETTA, is an extended-release steroid injection for osteoarthritis knee pain, and Pacira is testing it in shoulder osteoarthritis as well. The company sold its iovera cold-based nerve treatment business to Zimmer Biomet and is developing a gene therapy candidate for knee osteoarthritis. Customers are hospitals, ambulatory surgery centers and orthopedic practices, with reimbursement from Medicare and commercial insurers, some of which now pay separately for non-opioid pain drugs used in outpatient surgery. Pacira earns money from product sales through specialty distributors and wholesalers.

Pacira competes with generic bupivacaine and other local anesthetics, with Heron Therapeutics’ Zynrelef, with opioids and newer non-opioid painkillers, and in knee pain with generic steroids and hyaluronic acid injections. Its edge rests on clinical data and long experience with EXPAREL across many surgical procedures and an established hospital sales force. Investors who follow PCRX stock tend to watch EXPAREL sales and volume growth. Reimbursement changes that encourage non-opioid pain treatment are closely followed. ZILRETTA trial results, patent challenges and possible generic competition, debt and share buybacks are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward PCRX’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

65

Pulling it up

Holding it back

37 weighted scorers; 2 had no data today and are left out rather than counted as zero.

Technical · daily

—

Pulling it up

  • Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.

  • Where the price sits between its 52-week low and high.

  • The price change over the last 52 weeks.

Holding it back

  • SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.

  • SPY SMA 50 tracks the S&P 500 (SPY) position relative to its 50-period moving average.

  • SPY SMA 10 evaluates the S&P 500 (SPY) position relative to its 10-period simple moving average.

10 weighted scorers; 55 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
56

Technical score by timeframe

ChartScoreWeight
Hourly451
Monthly682
Quarterly662

Composite score, last 90 days

05010065Aug 23, 2026Nov 19, 2026Aug 23, 2026: 51Aug 24, 2026: 53Aug 25, 2026: 54Aug 26, 2026: 55Aug 27, 2026: 55Aug 28, 2026: 55Aug 29, 2026: 55Aug 30, 2026: 55Aug 31, 2026: 55Sep 1, 2026: 55Sep 2, 2026: 56Sep 4, 2026: 55Sep 5, 2026: 55Sep 6, 2026: 55Sep 7, 2026: 55Sep 8, 2026: 54Sep 9, 2026: 53Sep 10, 2026: 52Sep 11, 2026: 52Sep 12, 2026: 52Sep 13, 2026: 52Sep 14, 2026: 50Sep 15, 2026: 48Sep 16, 2026: 50Sep 17, 2026: 49Sep 18, 2026: 50Sep 19, 2026: 50Sep 20, 2026: 50Sep 21, 2026: 49Sep 22, 2026: 51Sep 23, 2026: 53Sep 24, 2026: 54Sep 25, 2026: 55Sep 26, 2026: 55Sep 27, 2026: 55Sep 28, 2026: 55Sep 29, 2026: 55Sep 30, 2026: 54Oct 1, 2026: 53Oct 2, 2026: 54Oct 3, 2026: 55Oct 4, 2026: 55Oct 5, 2026: 54Oct 6, 2026: 52Oct 7, 2026: 56Oct 8, 2026: 60Oct 9, 2026: 60Oct 10, 2026: 61Oct 11, 2026: 61Oct 12, 2026: 60Oct 13, 2026: 61Oct 14, 2026: 60Oct 15, 2026: 60Oct 16, 2026: 60Oct 17, 2026: 60Oct 18, 2026: 60Oct 19, 2026: 60Oct 20, 2026: 61Oct 21, 2026: 60Oct 22, 2026: 60Oct 23, 2026: 60Oct 24, 2026: 60Oct 25, 2026: 60Oct 26, 2026: 60Oct 27, 2026: 60Oct 28, 2026: 60Oct 29, 2026: 60Oct 30, 2026: 60Nov 1, 2026: 59Nov 2, 2026: 60Nov 3, 2026: 60Nov 4, 2026: 59Nov 5, 2026: 59Nov 6, 2026: 60Nov 7, 2026: 60Nov 10, 2026: 60Nov 11, 2026: 60Nov 12, 2026: 64Nov 13, 2026: 64Nov 14, 2026: 64Nov 15, 2026: 64Nov 16, 2026: 64Nov 17, 2026: 64Nov 18, 2026: 64Nov 19, 2026: 65
Show the daily numbers
DateComposite
Nov 19, 202665
Nov 18, 202664
Nov 17, 202664
Nov 16, 202664
Nov 15, 202664
Nov 14, 202664
Nov 13, 202664
Nov 12, 202664
Nov 11, 202660
Nov 10, 202660
Nov 7, 202660
Nov 6, 202660
Nov 5, 202659
Nov 4, 202659
Nov 3, 202660
Nov 2, 202660
Nov 1, 202659
Oct 30, 202660
Oct 29, 202660
Oct 28, 202660
Oct 27, 202660
Oct 26, 202660
Oct 25, 202660
Oct 24, 202660
Oct 23, 202660
Oct 22, 202660
Oct 21, 202660
Oct 20, 202661
Oct 19, 202660
Oct 18, 202660
Oct 17, 202660
Oct 16, 202660
Oct 15, 202660
Oct 14, 202660
Oct 13, 202661
Oct 12, 202660
Oct 11, 202661
Oct 10, 202661
Oct 9, 202660
Oct 8, 202660
Oct 7, 202656
Oct 6, 202652
Oct 5, 202654
Oct 4, 202655
Oct 3, 202655
Oct 2, 202654
Oct 1, 202653
Sep 30, 202654
Sep 29, 202655
Sep 28, 202655
Sep 27, 202655
Sep 26, 202655
Sep 25, 202655
Sep 24, 202654
Sep 23, 202653
Sep 22, 202651
Sep 21, 202649
Sep 20, 202650
Sep 19, 202650
Sep 18, 202650
Sep 17, 202649
Sep 16, 202650
Sep 15, 202648
Sep 14, 202650
Sep 13, 202652
Sep 12, 202652
Sep 11, 202652
Sep 10, 202652
Sep 9, 202653
Sep 8, 202654
Sep 7, 202655
Sep 6, 202655
Sep 5, 202655
Sep 4, 202655
Sep 2, 202656
Sep 1, 202655
Aug 31, 202655
Aug 30, 202655
Aug 29, 202655
Aug 28, 202655
Aug 27, 202655
Aug 26, 202655
Aug 25, 202654
Aug 24, 202653
Aug 23, 202651

Key facts

Market cap
$1.5B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.22
Risk grade (1–10)
5
Next earnings
Nov 5, 2026

Questions

What is PCRX's stock rating today?

PCRX scores 65/100 (Neutral) as of Nov 19, 2026: technical 63, fundamental 65, and news sentiment 56, which is shown but not counted. Scores are recomputed every night.

What does Pacira BioSciences do?

Pacira BioSciences (PCRX) is a U.S. pharmaceutical company focused on non-opioid treatments for pain.

Is PCRX stock a buy?

The score is not a buy or sell recommendation. A 65 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the PCRX score calculated?

47 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 10 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

PCRX stock score

HTML

<a href="https://stocksscores.com/stocks/pcrx/"><img src="https://stocksscores.com/stocks/pcrx/badge.svg" alt="PCRX stock score" height="20"></a>

Markdown

[![PCRX stock score](https://stocksscores.com/stocks/pcrx/badge.svg)](https://stocksscores.com/stocks/pcrx/)